Navigation Links
Genta Clinical Programs Featured at American Society of Hematology Meeting
Date:12/4/2007

Phase 3 CLL Survival Analysis Selected for ASH Press Briefing

BERKELEY HEIGHTS, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that several abstracts related to the Company's clinical programs will be featured at the annual meeting of the American Society of Hematology (ASH) in Atlanta, GA during December 7-11, 2007. Programs involving Genasense(R) (oblimersen sodium) Injection, Genta's lead anticancer compound, and G4544, a new oral drug for bone diseases, were released in abstracts published in the meeting proceedings, as follows:

-- Addition of oblimersen (Bcl-2 antisense) to

fludarabine/cyclophosphamide for relapsed/refractory chronic

lymphocytic leukemia extends survival in patients who achieve CR/nPR:

Results from a randomized Phase 3 study.

Oral session: Tuesday, December 11, 2007; 7:30 am

Note: This abstract has been selected for a featured press briefing

sponsored by ASH on Sunday December 9 at 9:30 am.

-- Oblimersen (Genasense(R)), a phosphorothioate Bcl-2 antisense

oligonucleotide (ASO), can be safely administered by bolus subcutaneous

(SC) injection and brief IV Infusion. Publication.

-- Phase 1 assessment of G4544, an orally bioavailable formulation of

gallium nitrate. Publication.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...29 FUJIFILM Medical Systems USA, I...raphy (FFDM) with over 7,000 installations, is ple...irst time in the US. The Aspire HD combines the u...) next generation detector technology and the smal...spatial resolution at a reduced dose for the patie...
(Date:11/28/2009)...8 Siemens Healthcare redefines pr... (Total imaging matrix) technology and with its n...h technologies are introduced in the new MAGNETOM ...kyra* 3T scanners at the 95th Scientific Assembly ...North America (RSNA) from November 29 to December ...
(Date:11/27/2009)... 27 At the upcoming Radiological S...ting Sunday, Royal Philips Electronics ( PHG, AEX:...maging and informatics solutions designed to direc...oviders, by delivering meaningful imaging innovati... points and easy upgradability. This focus will e...
Breaking Medicine Technology:FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 2FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 3FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 4Siemens Introduces Its New Power Couple at RSNA 2009 2Siemens Introduces Its New Power Couple at RSNA 2009 3Siemens Introduces Its New Power Couple at RSNA 2009 4Siemens Introduces Its New Power Couple at RSNA 2009 5Siemens Introduces Its New Power Couple at RSNA 2009 6Siemens Introduces Its New Power Couple at RSNA 2009 7Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4BioConference Live Kicks off Three Day Online Event for Life Science and Biotech Communities Today at 9 3A00 AM Eastern 61505 1BioConference Live Kicks off Three Day Online Event for Life Science and Biotech Communities Today at 9 3A00 AM Eastern 61505 2BioConference Live Kicks off Three Day Online Event for Life Science and Biotech Communities Today at 9 3A00 AM Eastern 61505 3NYC Chiropractor Adds New Therapy for Chronic Back Neck and Joint Pain to Downtown Practice 61503 1NYC Chiropractor Adds New Therapy for Chronic Back Neck and Joint Pain to Downtown Practice 61503 2Obesity Rates Will Continue to Increase Drive Health Care Costs in New Jersey in Next Decade According to New Study 61501 1Obesity Rates Will Continue to Increase Drive Health Care Costs in New Jersey in Next Decade According to New Study 61501 2
...V-1 monitoring technology used to validate results...w integrase inhibitor,Isentress, approved last wee...Diagnostics, COBAS(R) HIV-1 AMPLICOR viral load te...generically known as Raltegravir, is an HIV integr...ation of the virus by,blocking insertion of HIV ge...
...eatment Significantly Effective at Eight Weeks, C... of,its kind on mood stabilizers, scientists from ...two other centers demonstrated that divalproex,sod...mproving symptoms of,bipolar I disorder in childre...today at the annual meeting of the American Academ...
Other Medicine Technology:Roche Diagnostics' HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug 2Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder 2Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder 3Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder 4
(Date:11/29/2009)...ssing someone get blamed for something leads to mo... , SUNDAY, Nov. 29 (HealthDay News) -- The...ts, even when the target is innocent. , Researc...one else for a problem, even if it,s an unfair acc...ming others, too. , "When we see others protec...
(Date:11/28/2009)... , CHICAGO, Nov. 28 Welcome...CS solution for the clinical routine from Siemen...nd Communications System (PACS) from Siemens whe...ce, syngo .plaza is poised to change the way ...veiling this innovation at the 95th Scientific A...
(Date:11/27/2009)... , BEDFORD, Mass., Nov. 27 /PRNewswire-FirstC...ompany"), a supplier of precision technology produ...t an annual meeting of the Company,s shareholders ...e time and location of the meeting will be announc...mpany received a requisition notice from Stephen B...
(Date:11/27/2009)... , ROCHESTER, N.Y., Nov. 27 /PRNewswire-USNews...ealth care provider and fortunately every year, ne...evention. But do all vaccines boost immunity for t...tional ,booster shots, needed to keep immunity str...the Journal of the American Academy of Pediatrics,...
(Date:11/27/2009)...ng rates to bring unprecedented medical, economic ... 27 (HealthDay News) -- The number of people with ...e over the next 25 years, a new study predicts. ,...1 million people with the disease, up from 23.7 mi...reating people with diabetes will triple, the stud...
Breaking Medicine News(10 mins):Health News:When Accusations Start to Fly, They Multiply 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3
...f Millions In Rebates to Medicaid Program , , WAS...ave joined in two whistleblower suits filed in the...cturer, Wyeth, alleging that the company knowingly...As a result, Wyeth allegedly avoided paying hundre...
... and cell biologists have identified a new molecul...tate cancers. , In a preclinical study led by M...aneous inactivation of two particular genesknown ...enes could result in benign tumors, but when those...
...ay help some , , MONDAY, May 18 (HealthDay...he other an appliance that adjusts the jaw -- migh...ough to treat. , In sleep apnea, the upper airway ...ally treated with a device that increases air pres...
... APD ) today announced it has sold three of its ...n, Inc. (LMI), the largest provider of durable med...in the northeast, based in Mount Vernon, N.Y. Ter... the Air Products Healthcare LLC Group, namely Gen...
...May 13, 2009, as Minnesota became the first state ...alth provider into state statute - enabling studen...ene Practitioner (ADHP) model to become licensed t... Therapist providers in the state. Minnesota Gover...
...006 , , DETROIT, May 18 A just-completed financi...the Michigan Office of Financial and Insurance Reg...ancial statements over the audit,s four-year perio... by the National Association of Insurance Commissi...
Other Medicine News:Health News:U.S. and 16 States Join Suits Against Pharmaceutical Giant, Wyeth 2Health News:U.S. and 16 States Join Suits Against Pharmaceutical Giant, Wyeth 3Health News:Research reveals molecular pathway behind invasive prostate cancers 2Health News:New Options Offered for Sleep Apnea 2Health News:New Options Offered for Sleep Apnea 3Health News:New Options Offered for Sleep Apnea 4Health News:Air Products Sells Three U.S. Healthcare Businesses to Landauer-Metropolitan 2Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 2Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 3Health News:State Audit of Blue Cross Blue Shield of Michigan Shows Company in Compliance with State and National Accounting Guidelines 2
... come with five legs for extra stability. Adjustab...el 6"). 2" ball bearing swivel hard rubber castors...ry, available in black vinyl as standard, other co...red, padded, upholstered backrest, with vertical a...
Lacrimal Cannula, 19 g / 23 g. Straight
Anterior Chamber Needle, 21 g
Nucleus Hydrodissection Cannula, 25 g
Medicine Products: